Join to View Full Profile
500 Arcola RoadCollegeville, PA 19426
Phone+1 484-865-4147
Dr. Sbar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I have worked in the pharmaceutical industry for 10+ years developing small molecule and immune checkpoint inhibitors in lung cancer
Clinical Expertise
- Immunotherapy, Thoracic oncology, Gene Targeting, Receptor Protein-Tyrosine Kinases
Education & Training
Cooper Medical School of Rowan University/Cooper University HospitalFellowship, Hematology and Medical Oncology, 1998 - 2001
Abington Memorial HospitalResidency, Internal Medicine, 1995 - 1998- Temple UniversityB.A., 1998
Philadelphia College of Osteopathic MedicineClass of 1994
Awards, Honors, & Recognition
- Golden Apple Teaching Award UMDNJ - Camden Campus, 2001
Clinical Trials
- ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer Start of enrollment: 2011 Jun 16
- Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO Start of enrollment: 2011 Dec 26
- ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. Start of enrollment: 2013 May 09
- Join now to see all
Publications & Presentations
PubMed
- 10 citationsManagement of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis.Qing Zhou, Yi-Long Wu, Jesus Corral, Kazuhiko Nakagawa, Edward B. Garon
Future Oncology. 2019-03-06 - 330 citationsImprovement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating...Tony Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa
Journal of Clinical Oncology. 2018-06-04 - 773 citationsDacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase...Yi-Long Wu, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa
The Lancet. Oncology. 2017-11-01
Research History
- Medical Director - Bristol-Myers Squibb2007 - 2013
Professional Memberships
- Member
- Member
- European Society of Medical OncologyMember
- International Association for the Study of Lung CancerMember
- Society of Immunotherapy in CancerMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
